Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Pinnacle Associates Ltd.

Pinnacle Associates Ltd. increased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report) by 83.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,951 shares of the biotechnology company’s stock after acquiring an additional 41,836 shares during the quarter. Pinnacle Associates Ltd.’s holdings in Sarepta Therapeutics were worth $11,484,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SRPT. Riggs Asset Managment Co. Inc. increased its stake in shares of Sarepta Therapeutics by 33.3% during the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 75 shares during the period. EP Wealth Advisors LLC increased its stake in shares of Sarepta Therapeutics by 2.1% during the second quarter. EP Wealth Advisors LLC now owns 4,899 shares of the biotechnology company’s stock worth $774,000 after acquiring an additional 103 shares during the period. Cambridge Investment Research Advisors Inc. increased its stake in shares of Sarepta Therapeutics by 1.9% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 6,331 shares of the biotechnology company’s stock worth $1,000,000 after acquiring an additional 120 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Sarepta Therapeutics by 16.9% during the third quarter. Nisa Investment Advisors LLC now owns 1,070 shares of the biotechnology company’s stock worth $134,000 after acquiring an additional 155 shares during the period. Finally, Innealta Capital LLC purchased a new stake in Sarepta Therapeutics during the second quarter worth about $31,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Ian Michael Estepan sold 5,985 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael Andrew Chambers bought 37,038 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was acquired at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

SRPT has been the topic of a number of research analyst reports. Citigroup decreased their price objective on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Needham & Company LLC reissued a “buy” rating and set a $205.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 14th. William Blair raised shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Barclays decreased their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Two analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $182.95.

Read Our Latest Stock Analysis on Sarepta Therapeutics

Sarepta Therapeutics Stock Down 1.9 %

Shares of NASDAQ SRPT opened at $127.78 on Thursday. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The firm’s 50 day moving average price is $128.07 and its 200 day moving average price is $132.57. The firm has a market cap of $12.08 billion, a P/E ratio of 1,161.64 and a beta of 0.82. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.06. The firm had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. Sarepta Therapeutics’s revenue was up 38.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.27) earnings per share. As a group, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current year.

Sarepta Therapeutics Profile

(Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Featured Articles

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.